Skip to main content

Table 2 Primary outcome measures

From: Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

  Mean (SD) change from baseline to 26 weeks Mean (95% CI) changes from baseline (liraglutide vs placebo) P value
Liraglutide (n = 23) Placebo (n = 26)
LV diastolic function
 E in mL/s (SD) − 33 (59) 23 (62) − 56 (− 91 to − 21) 0.002
 A in mL/s (SD) 31 (77) 23 (62) 3 (− 35 to 41) 0.88
 E/A (SD) − 0.19 (0.31) − 0.00 (0.17) − 0.17 (− 0.27 to − 0.06) 0.003
 Edec in mL/s2 × 10−3 (SD) − 0.6 (0.6) 0.3 (0.9) − 0.9 (− 1.3 to − 0.4) < 0.001
 Ea in cm/s (SD) 0.4 (1.8) − 0.2 (1.7) 0.4 (− 0.6 to 1.4) 0.40
 E/Ea (SD) − 0.9 (2.6) 0.6 (1.9) − 1.8 (− 3.0 to − 0.6) 0.005
LV systolic function
 Stroke volume in mL (SD) − 4 (13) 5 (12) − 9 (−16 to −2) 0.02
 Ejection fraction in (% (SD) − 1 (5) 1 (5) − 3 (−6 to − 0.1) 0.02
 Cardiac output in L/min (SD) 0.0 (0.9) 0.3 (1.1) − 0.4 (− 0.9 to 0.2) 0.21
 Cardiac index in L/min/m2 (SD) − 0.0 (0.4) 0.1 (0.5) − 0.1 (− 0.4 to 0.1) 0.27
 Peak ejection rate in mL/s (SD) − 28 (89) 24 (82) − 46 (−95 to 3) 0.07
  1. Within group and between group changes in left ventricular diastolic and systolic function between baseline and 26 weeks (primary outcome)
  2. E early transmitral peak flow rate, A late transmitral peak flow rate, Edec early deceleration peak of transmitral flow rate, Ea early peak mitral annular septal tissue velocity